Deep Eutectic Solvent to decrease the cost of CO2 capture processes.

International audienc

Patterns of care and outcomes of 417 patients with METAstatic SYNovial sarcoma (METASYN): real-life data from the French Sarcoma Group (FSG)

International audienceBackground: Synovial sarcoma (SS) occurs in both adult and pediatric patients. The primary aim of this study is to describe the outcomes, prognostic factors, and treatment of patients with metastatic SS within a nationwide cohort.Patients and methods: All pediatric and adult patients with metastatic SS are registered in the French Sarcoma Group database. Data were collected from the national database https://conticabase.sarcomabcb.org/ up to March 2020. Descriptive and comparative analyses were conducted using SAS 9.4 and Stata Special Edition 16.1 software.Results: Between January 1981 and December 2019, 417 patients with metastatic SS from 17 French sarcoma centers were included, including 64 (15.3%) under the age of 26 years. Median age was 42.5 years (range 9-87 years). The metastases were synchronous (cohort 1) or metachronous (cohort 2) in 18.9% (N = 79) and 81.1% (N = 338) patients, respectively. Median overall survival (OS) from the date of metastasis was 22.3 months (95% confidence interval 19.7-24.1 months). First-line chemotherapy without ifosfamide and/or doxorubicin was unfavorable for progression-free survival and OS (P 12 months, local therapy, and ifosfamide in the first metastatic line were independent favorable prognostic factors.Conclusions: The outcome of patients with metastatic SS is influenced by local treatment, management in reference centers, and cytotoxic treatments given in the perioperative and metastatic setting

Neoadjuvant chemotherapy in high-risk soft tissue sarcomas: A Sarculator-based risk stratification analysis of the ISG-STS 1001 randomized trial

none79Background: The value of neoadjuvant chemotherapy in soft tissue sarcoma (STS) is not completely understood. This study investigated the benefit of neoadjuvant chemotherapy according to prognostic stratification based on the Sarculator nomogram for STS. Methods: This study analyzed data from ISG-STS 1001, a randomized study that tested 3 cycles of neoadjuvant anthracycline plus ifosfamide (AI) or histology-tailored (HT) chemotherapy in adult patients with STS. The 10-year predicted overall survival (pr-OS) was estimated with the Sarculator and was stratified into higher (10-year pr-OS .99). In lower risk patients, the 3- and 5-year Sarculator-predicted and study-observed OS rates were 0.85 and 0.80, respectively, and 0.89 and 0.82, respectively, in the AI arm (P =.507); the corresponding figures in the HT arm were 0.87 and 0.81, respectively, and 0.86 and 0.74, respectively (P =.105). Conclusions: High-risk patients treated with AI performed better than predicted, and this adds to the evidence for the efficacy of neoadjuvant AI in STS. Lay Summary: People affected by soft tissue sarcomas of the extremities and trunk wall are at some risk of developing metastasis after surgery. Preoperative or postoperative chemotherapy has been tested in clinical trials to reduce the chances of distant metastasis. However, study findings have not been conclusive. This study stratified the risk of metastasis for people affected by sarcomas who were included in a clinical trial testing neoadjuvant chemotherapy. Exploiting the prognostic nomogram Sarculator, it found a benefit for chemotherapy when the predicted risk, based on patient and tumor characteristics, was high.nonePasquali S.; Palmerini E.; Quagliuolo V.; Martin-Broto J.; Lopez-Pousa A.; Grignani G.; Brunello A.; Blay J.-Y.; Tendero O.; Diaz-Beveridge R.; Ferraresi V.; Lugowska I.; Infante G.; Braglia L.; Merlo D.F.; Fontana V.; Marchesi E.; Donati D.M.; Palassini E.; Bianchi G.; Marrari A.; Morosi C.; Stacchiotti S.; Bague S.; Coindre J.M.; Dei Tos A.P.; Picci P.; Bruzzi P.; Miceli R.; Casali P.G.; Gronchi A.; Dani C.; Villa C.; Messina A.; Rusi L.; Nuzzo A.M.; Nuzzo C.; De Paoli A.; Buonadonna A.; Comandone A.; Boglione A.; Livi L.; Greto D.; Riva N.; Monti M.; Pennacchioli E.; De Pas T.; Ippolito V.; Ledesma P.; Redondo A.; Valverde C.; Bratos R.; Cruz J.; Martinez Trufero J.; Cubedo R.; Sevilla I.; Luna P.; Lopez R.; Sancho P.; Bally O.; Brahmi M.; Ray-Coquard I.; Cassier P.; Marques N.; Tassy L.; Boudou-Rouquette P.; Tlemsani C.; Alexandre J.; Goldwasser F.; Bompas E.; Rolland F.; Perrin C.; Talarmin M.; Italiano A.; Toulmonde M.; Laramas M.; Bay J.-O.; Dubray-Longeras P.; Rutkowski P.Pasquali, S.; Palmerini, E.; Quagliuolo, V.; Martin-Broto, J.; Lopez-Pousa, A.; Grignani, G.; Brunello, A.; Blay, J. -Y.; Tendero, O.; Diaz-Beveridge, R.; Ferraresi, V.; Lugowska, I.; Infante, G.; Braglia, L.; Merlo, D. F.; Fontana, V.; Marchesi, E.; Donati, D. M.; Palassini, E.; Bianchi, G.; Marrari, A.; Morosi, C.; Stacchiotti, S.; Bague, S.; Coindre, J. M.; Dei Tos, A. P.; Picci, P.; Bruzzi, P.; Miceli, R.; Casali, P. G.; Gronchi, A.; Dani, C.; Villa, C.; Messina, A.; Rusi, L.; Nuzzo, A. M.; Nuzzo, C.; De Paoli, A.; Buonadonna, A.; Comandone, A.; Boglione, A.; Livi, L.; Greto, D.; Riva, N.; Monti, M.; Pennacchioli, E.; De Pas, T.; Ippolito, V.; Ledesma, P.; Redondo, A.; Valverde, C.; Bratos, R.; Cruz, J.; Martinez Trufero, J.; Cubedo, R.; Sevilla, I.; Luna, P.; Lopez, R.; Sancho, P.; Bally, O.; Brahmi, M.; Ray-Coquard, I.; Cassier, P.; Marques, N.; Tassy, L.; Boudou-Rouquette, P.; Tlemsani, C.; Alexandre, J.; Goldwasser, F.; Bompas, E.; Rolland, F.; Perrin, C.; Talarmin, M.; Italiano, A.; Toulmonde, M.; Laramas, M.; Bay, J. -O.; Dubray-Longeras, P.; Rutkowski, P